Immediate Impact
57 standout
Citing Papers
Pancreatic cancer
2025 Standout
The present and future of bispecific antibodies for cancer therapy
2024 Standout
Works of Scott R. Berry being referenced
CCTG CO.26 trial: A phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC).
2019
Real‐world outcomes of FOLFIRINOX vs gemcitabine and nab‐paclitaxel in advanced pancreatic cancer: A population‐based propensity score‐weighted analysis
2019
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Scott R. Berry | 272 | 130 | 90 | 30 | 480 | |
| Paul M. Walsh | 256 | 91 | 80 | 28 | 470 | |
| W.K. Evans | 225 | 158 | 175 | 26 | 489 | |
| Anne Prenzler | 171 | 115 | 111 | 29 | 559 | |
| Natalie Fitzgerald | 265 | 133 | 104 | 26 | 562 | |
| Yueh‐Hsin Wang | 251 | 58 | 118 | 23 | 523 | |
| Temidayo Fadelu | 340 | 105 | 74 | 36 | 574 | |
| Pierre K. Isogai | 194 | 178 | 114 | 24 | 439 | |
| Henrik W. Finnern | 199 | 121 | 198 | 23 | 574 | |
| Louise Crathorne | 153 | 125 | 86 | 31 | 518 | |
| Fadila Farsi | 187 | 84 | 167 | 39 | 501 |
All Works
Loading papers...